My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

Johnson & Johnson (JNJ) — RQD Stock Rating Cockpit

$267.10 -2.05% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $266.76

Johnson & Johnson (JNJ) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (67.9% gross margin, 26% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $642.99B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JNJ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, Johnson & Johnson (NYSE: JNJ) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $267.10 (-2.05% 1D, market cap $642.99B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, JNJ ranks #14 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JNJ compare to ABBV and MRK in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JNJ carries a Roarable B+ (76/100 RQD), trailing P/E of 24.7x, gross margin of 67.9%, and ROIC of 25.5%. By comparison, ABBV (AbbVie Inc.) holds a B+ grade (76/100 RQD, P/E 121.6x, ROIC 29.0%, cap $501.14B) and MRK (Merck & Company Inc.) posts a C+ grade (69/100 RQD, P/E 19.8x, ROIC 20.7%, cap $327.24B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JNJ?
▼

Per JNJ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000200406), Johnson & Johnson generated $94.19B in revenue (+6.0% YoY), $26.80B in net income, and $19.70B in free cash flow against $199.21B in total assets and $39.44B in total debt. Key quantitative strengths: Strong cash generator (67.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 JNJ TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $JNJ, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $JNJ R/R 3.6 : 1 • RQD 76/100 (B+)
$JNJ
Spot $267.10
1. GET IN (ENTRY)
$265.50–$268.44
2. HARD STOP (SUP)
$256.15 (-4.1%)
3. GET OUT (T1/T2)
$290.60 / $306.63
STOP-LOSS FLOOR (SUP $256.15): Hard stop sits 4.1% below spot to cap downside below key institutional support. If $JNJ closes a daily candle below $256.15, step aside.
PROFIT TARGETS (RES $290.60 / $306.63): Scale out 50% at T1 (+8.8%) and trail stop to breakeven for T2 (+14.8%).
Want this $JNJ sheet + Today's Top 3 Trades emailed free? Paper Trade $JNJ →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $JNJ Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $266.75 (-0.13%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 20.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510076
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk A-
Cash (15)Whales (13)SEC (18)Macro (15)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+8.1% Base Target
$341 Bull$289 Base$219 Bear
📬 FREE JNJ RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JNJ)Realized 20D OHLCV Swing Band: ±2.9%
Deterministic 5-Pillar Attribution (76/100 Composite)
🔍 WHY JNJ SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 5.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 20.9% FCF Margin ($19.70B FCF) & 67.9% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning13/20 pts (-7 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-7 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
84
Grade A$272.63+3% Next Q
Q2 (-2Q)
81
Grade A-$280.77+1.9% Next Q
Q3 (-1Q)
79
Grade A-$286.11-6.6% Next Q
Current
76
Grade B+$267.10+7.6% Hist 90D α
Trajectory: A (84) → B+ (76)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the JNJ Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, JNJ faces multiple-compression risk if 24.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 65.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($268.43) or 200D SMA ($251.77) invalidates the momentum regime and cuts Target Base ($288.74) toward Bear Floor ($219.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JNJ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JNJ Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
40.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.59>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE78% OF RANGE
L: $200$267.10H: $286
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (67.9% gross margin and healthy balance-sheet cushion).

Factor Grade: BRQD 15 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B-RQD 28 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 33 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bullish on JNJ

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (75)

25.5% ROIC with 67.9% gross margin and 2.97% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 5.59 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (72)

28/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like JNJ
  • ✓Strong cash generator (67.9% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (JNJ Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
JNJ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.04%📐 HORIZONTAL RANGE
2026-11-22O $272.7H $272.7L $267.1C $267.1VOL 9.84M
$291.4$269.6$247.8$226.1$204.3RES $287.4SUP $245.0$267.12026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 25.5% vs WACC 7.6%)

JNJ Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $308.27 vs Spot $267.10
MODESTLY UNDERVALUED (+13.4%)
Undervalued Zone (< $262) Fair Value Corridor ($262–$355) Overvalued (> $355)
$267
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own JNJ Growth & WACC Assumptions

YOUR DCF TARGET
$441.29
5-Yr Annual FCF Growth Rate: 15.5%
Discount Rate (WACC Hurdle): 7.6%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: +13.4% vs $267.10 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JNJ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
18.4%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on JNJ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JNJ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JNJ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JNJ)

Health Care Rank #14 of 1015 ⚔️ ABBV vs JNJ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JNJ vs. ABBV, MRK, NVS, AZN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Johnson & Johnson (JNJ) ranks #14 by composite RQD confidence (76/100, grade B+) and #2 by equity capitalization ($642.99B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
JNJ ACTIVE
Johnson & Johnson
B+ 76/100 24.7x 67.9% 25.5% -2.05% $642.99B Benchmark Subject
ABBV
AbbVie Inc.
B+ 76/100 121.6x 70.2% 29.0% -0.87% $501.14B /abbv-vs-jnj →
MRK
Merck & Company Inc.
C+ 69/100 19.8x 74.8% 20.7% -3.66% $327.24B /mrk-vs-jnj →
NVS
Novartis AG
D+ 56/100 32.8x — 9.9% -2.55% $288.61B /nvs-vs-jnj →
AZN
AstraZeneca PLC
D+ 56/100 32.8x — 9.9% -1.91% $271.90B /azn-vs-jnj →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000200406 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-28), Johnson & Johnson (JNJ) reported GAAP revenue of $94.19B (+6.0% vs. FY2024 revenue of $88.82B , and +10.6% cumulative change since FY2023) , GAAP net income of $26.80B, operating cash flow of $24.53B, and free cash flow of $19.70B (-0.7% YoY). On the balance sheet, JNJ closed FY2025 with $199.21B in total assets against $39.44B in total debt (Altman Z-Score: 5.59, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-28 $94.19B $26.80B $24.53B $19.70B $199.21B $39.44B
FY2024 (FY) 2024-12-29 $88.82B $14.07B $24.27B $19.84B $180.10B $30.65B
FY2023 (FY) 2023-12-31 $85.16B $35.15B $22.79B $18.96B $364.37B $85.26B

3. JNJ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, Johnson & Johnson (NYSE: JNJ) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $267.10 (-2.05% 1D, market cap $642.99B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, JNJ ranks #14 in composite RQD confidence.

How does JNJ compare to ABBV and MRK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JNJ carries a Roarable B+ (76/100 RQD), trailing P/E of 24.7x, gross margin of 67.9%, and ROIC of 25.5%. By comparison, ABBV (AbbVie Inc.) holds a B+ grade (76/100 RQD, P/E 121.6x, ROIC 29.0%, cap $501.14B) and MRK (Merck & Company Inc.) posts a C+ grade (69/100 RQD, P/E 19.8x, ROIC 20.7%, cap $327.24B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JNJ?

Per JNJ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000200406), Johnson & Johnson generated $94.19B in revenue (+6.0% YoY), $26.80B in net income, and $19.70B in free cash flow against $199.21B in total assets and $39.44B in total debt. Key quantitative strengths: Strong cash generator (67.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JNJ trading relative to its 50-day, 200-day, and 52-week technical levels?

JNJ last traded at $267.10 (-2.05% on volume of 9,842,246 shares), positioning the stock -0.50% below its 50-day simple moving average ($268.43) and +6.09% above its 200-day simple moving average ($251.77). Across its 52-week range of $199.91 to $286.11, JNJ sits at the 77.9% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±2.9% ($259.35 to $274.85).

ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ SEC XBRL & RQD VERIFIED

JNJ — Johnson & Johnson: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-28

1. Roarable Rating Brief: What This Means to a Prospective Investor

Johnson & Johnson (JNJ) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $267.10 (-2.05% 1D, market capitalization $642.99B).

  • Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 25.5%, gross margin of 67.9%, operating margin of 34.7%, and free cash flow yield of 2.97%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 5.59, Piotroski F-Score of 8/9, and Debt/Equity of 0.48x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Johnson & Johnson (JNJ) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. It operates in this industry with a market capitalization of $662.5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-28), Johnson & Johnson (JNJ) reported $94.19B in annual revenue (up from $88.82B in FY2024, +6.0% YoY) and $26.80B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($85.16B revenue, $35.15B net income) through FY2025, JNJ scaled operating cash flow to $24.53B and free cash flow to $19.70B, backed by $199.21B in total assets against $39.44B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 76/100): Strong cash generator (67.9% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $199.91 – $286.11 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 24.7x trailing P/E and 18.5x EV/EBITDA against 34.7% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), JNJ carries a macro regime beta of 1.08 and gross margin of 67.9%.

  • Key Question #1: Can JNJ sustain or expand its 34.7% operating margin and 25.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $94.19B and free cash flow of $19.70B, how will capital allocation balance growth reinvestment against $39.44B in total debt?
  • Key Question #3: How sensitive is JNJ's 23.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

JNJ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Johnson & Johnson (JNJ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JNJ Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JNJ Bull vs. Bear Conversation Board — What's Your Call at $267.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JNJ 🐻 33% BEARISH CONVICTION
1. Pick Your Side on JNJ:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $314.18 (+15.0%)
📌 Pinned Debate

Per the RQD rating, forensic balance-sheet metrics (Altman Z 5.59, Piotroski F 8/9, Debt/Equity 0.48) and 25.5% ROIC support a high-qua

Per the RQD rating, forensic balance-sheet metrics (Altman Z 5.59, Piotroski F 8/9, Debt/Equity 0.48) and 25.5% ROIC support a high-quality financial profile.. When you look under the hood at JNJ, Fundamental Cash Engine is 15/20 with 67.9% gross margins and 25.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (18/20) has been quietly accumulating below $282.02. My 12M target is $314.18.

ArenaChamp_24 🐂 BULL

@DeepValue_CFA Agree on the RQD 83/100 quality, though with 1.08 beta I'm scaling in with half-size at $273.20 and keeping dry powder in case we test $254.08.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $226.76 (-17.0%)
Spot @ $273.20

Per the news wire, shares fell on weak medical device sales and medtech unit concerns, while the FCF yield of 2.97% implies a premium v

Per the news wire, shares fell on weak medical device sales and medtech unit concerns, while the FCF yield of 2.97% implies a premium valuation.. Look at the math on JNJ: paying 24.7x trailing P/E for 25.5% ROIC and 34.7% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $240.42 before getting long.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
4. Editorial Investigations, FRED Macro & Interactive Tools
LIVE TAPE